Kisspeptin vs Pitavastatin
Emerging vs FDA Approved
synergistic Mechanism-based · 49% Pitavastatin helps manage estrogen conversion from Kisspeptin. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
Kisspeptin Pitavastatin
Weight 1,213.42 Da (KP-10) / 6,087 Da (KP-54) 421.46 Da
Half-life ~4 minutes (KP-10), ~28-32 minutes (KP-54) ~12 hours
Chain 10-54 amino acids —
Type Neuropeptide family (RFamide) Synthetic statin (C25H24FNO4)
Key Benefits
Kisspeptin
01 Potent reproductive hormone stimulation (LH/FSH)
02 Restoration of natural testosterone production
03 Fertility enhancement
04 Sexual function support
05 Hypogonadism treatment potential
Pitavastatin
01 Minimal CYP450 metabolism — does not interact with CYP3A4, making it ideal for users taking multiple compounds
02 Lowest risk of new-onset diabetes among all statins, supported by the LIVES study and J-PREDICT trial data
03 LDL reductions of 38-45% at standard doses (2-4 mg/day)
04 More robust HDL-raising effect (5-15%) compared to other statins in the class
05 12-hour half-life supports convenient once-daily dosing
06 Favorable safety profile with low incidence of muscle-related side effects
07 Compatible with CYP3A4 inhibitors and inducers that would alter levels of other statins
08 Effective at counteracting AAS-induced lipid disturbances without adding to drug interaction burden
Dosing Protocols
Kisspeptin
100-200 mcg per injection / Single dose for testing, or 2-3 times weekly (NEVER daily - causes desensitization)
Gonadotropin stimulation 100-200mcg Single dose or 2-3x weekly
Fertility support 0.4-1.0 nmol/kg (50-150mcg) As directed by physician
Sexual function (clinical) 1 nmol/kg/h 75-minute IV infusion
Pitavastatin
1-4 mg/day / Once daily
Side Effects
Kisspeptin
Minimal acute side effects reported
Potential mild cardiovascular effects
Pitavastatin
Myalgia and muscle discomfort (approximately 3-5% of users) — generally mild and less frequent than with lipophilic statins
Headache
Minimal liver enzyme elevation — typically transient and clinically insignificant
Back pain
Constipation or diarrhea
Contraindications
Not recommended during pregnancy or breastfeeding
Caution with cardiovascular disease history
Daily dosing causes receptor desensitization
Active liver disease or unexplained persistent elevations in hepatic transaminases
Known hypersensitivity to pitavastatin or any excipients
Pregnancy and breastfeeding (Category X — statins are teratogenic)
Concomitant use with cyclosporine (significantly increases pitavastatin levels via OATP1B1 inhibition)
Concomitant use with lopinavir/ritonavir or atazanavir/ritonavir combinations
Research Evidence
Kisspeptin Pitavastatin
Status Emerging FDA Approved
References 4 studies 5 studies
Latest 2025 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.